Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

Figure 3

Time to a hemoglobin concentration ≥11 g/dL. Hemoglobin (Hb) measurements within 28 days of a red blood cell transfusion or whole blood transfusion were excluded. Patients not achieving a Hb level ≥11 g/dL between day 1 and end of the treatment period (EOTP, earlier of day 109 or end of study) were censored at their last Hb measurement prior to EOTP. Two patients in the ≥10 g/dL baseline-Hb group who had a baseline Hb level ≥11 g/dL were excluded from the analysis. A. Patients with a baseline Hb level < 10 g/dL. B. Patients with a baseline Hb level ≥10 g/dL.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us